Cumberland Pharmaceuticals Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Program.

Cumberland Pharmaceuticals has received FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy program. The FDA's Fast Track program facilitates the development and expedited review of drugs for serious or life-threatening conditions with unmet medical need. This designation allows Cumberland to have more frequent communication with the FDA and submit portions of its application for review.